# A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

> **NCT00002151** · PHASE2 · COMPLETED · sponsor: **Hoechst Marion Roussel** · enrollment: 200 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Celgosivir hydrochloride

## Key facts

- **NCT ID:** NCT00002151
- **Lead sponsor:** Hoechst Marion Roussel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002151, "A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*